Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients: data from the real-world registry PRAEGNANT = Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium : Real-World-Daten aus dem PRAEGNANT-Register

Background: Comprehensive data from prospective clinical trials have led to a high level of evidence establishing CDK4/6 inhibitors in combination with endocrine treatment (CDK4/6i + ET) as a standard for the treatment of HER2-negative, hormone receptor-positive (HER2− HR+) breast cancer patients in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Englert, Tobias (VerfasserIn) , Fasching, Peter Andreas (VerfasserIn) , Lüftner, Diana (VerfasserIn) , Hartkopf, Andreas D. (VerfasserIn) , Müller, Volkmar (VerfasserIn) , Kolberg, Hans-Christian (VerfasserIn) , Hadji, Peyman (VerfasserIn) , Tesch, Hans (VerfasserIn) , Häberle, Lothar (VerfasserIn) , Ettl, Johannes (VerfasserIn) , Wallwiener, Markus (VerfasserIn) , Beckmann, Matthias W. (VerfasserIn) , Hein, Alexander (VerfasserIn) , Belleville, Erik (VerfasserIn) , Uhrig, Sabrina (VerfasserIn) , Wimberger, Pauline (VerfasserIn) , Hielscher, Carsten (VerfasserIn) , Kurbacher, Christian M. (VerfasserIn) , Wuerstlein, Rachel (VerfasserIn) , Untch, Michael (VerfasserIn) , Ţăran, Florin-Andrei (VerfasserIn) , Enzinger, Hans-Martin (VerfasserIn) , Krabisch, Petra (VerfasserIn) , Welslau, Manfred (VerfasserIn) , Maasberg, Michael (VerfasserIn) , Hempel, Dirk (VerfasserIn) , Lux, Michael P. (VerfasserIn) , Michel, Laura L. (VerfasserIn) , Janni, Wolfgang (VerfasserIn) , Wallwiener, Diethelm (VerfasserIn) , Brucker, Sara Y. (VerfasserIn) , Fehm, Tanja (VerfasserIn) , Schneeweiss, Andreas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2022-07-12
In: Geburtshilfe und Frauenheilkunde
Year: 2022, Jahrgang: 82, Heft: 10, Pages: 1055-1067
ISSN:1438-8804
DOI:10.1055/a-1880-0087
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1880-0087
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1880-0087
Volltext
Verfasserangaben:authors: Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss

MARC

LEADER 00000caa a2200000 c 4500
001 1833842367
003 DE-627
005 20250325034309.0
007 cr uuu---uuuuu
008 230209s2022 xx |||||o 00| ||eng c
024 7 |a 10.1055/a-1880-0087  |2 doi 
035 |a (DE-627)1833842367 
035 |a (DE-599)KXP1833842367 
035 |a (OCoLC)1389535586 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Englert, Tobias  |e VerfasserIn  |0 (DE-588)1215290063  |0 (DE-627)172658447X  |4 aut 
245 1 0 |a Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients  |b data from the real-world registry PRAEGNANT = Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium : Real-World-Daten aus dem PRAEGNANT-Register  |c authors: Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss 
246 3 1 |a Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium  |b Real-World-Daten aus dem PRAEGNANT-Register 
264 1 |c 2022-07-12 
300 |b Diagramme 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 09.02.2023 
520 |a Background: Comprehensive data from prospective clinical trials have led to a high level of evidence establishing CDK4/6 inhibitors in combination with endocrine treatment (CDK4/6i + ET) as a standard for the treatment of HER2-negative, hormone receptor-positive (HER2− HR+) breast cancer patients in the first-line advanced therapy setting. Data on patient populations that have been treated in the real-world setting may provide an insight into changes of patient characteristics and prognosis over time. Methods: The data were extracted from the prospective real-world registry PRAEGNANT (NCT02338167). Patients had to have HER2− HR+ advanced breast cancer in the first-line metastatic setting. The chosen therapies were described as well as progression-free survival (PFS) and overall survival (OS) in relation to the given therapies and time periods during which they were indicated.</p> <p> <b>Results</b> CDK4/6 inhibitors have been rapidly implemented since their introduction in November 2016. In recent years (2018 - 2022), about 70 - 80% of the patient population have been treated with CDK4/6 inhibitors, while endocrine monotherapy was given to about 10% and chemotherapy to about 15% of all patients. The prognosis was worst in patients treated with chemotherapy. Recently, mainly patients with a good prognosis are being treated with endocrine monotherapy, and patients who are treated with chemotherapy have an unfavorable prognosis. The PFS and OS of patients treated with CDK4/6i + ET have remained similar over time despite changes in patient characteristics. Conclusion: A treatment with CDK4/6i + ET has rapidly become the therapy standard for patients in the first-line advanced breast cancer setting. After the implementation of CDK4/6i + ET, endocrine monotherapy is only given to patients with a very favorable prognosis, while chemotherapy is provided to patients with a rather unfavorable prognosis. These changes in patient characteristics did not seem to influence the prognosis of patients treated with CDK4/6i + ET. 
546 |a Text englisch, Zusammenfassung deutsch 
700 1 |8 1\p  |a Fasching, Peter Andreas  |d 1975-  |e VerfasserIn  |0 (DE-588)129068780  |0 (DE-627)388703040  |0 (DE-576)297477099  |4 aut 
700 1 |a Lüftner, Diana  |e VerfasserIn  |4 aut 
700 1 |a Hartkopf, Andreas D.  |e VerfasserIn  |4 aut 
700 1 |a Müller, Volkmar  |e VerfasserIn  |4 aut 
700 1 |a Kolberg, Hans-Christian  |e VerfasserIn  |4 aut 
700 1 |a Hadji, Peyman  |e VerfasserIn  |4 aut 
700 1 |a Tesch, Hans  |e VerfasserIn  |4 aut 
700 1 |a Häberle, Lothar  |e VerfasserIn  |4 aut 
700 1 |a Ettl, Johannes  |e VerfasserIn  |4 aut 
700 1 |a Wallwiener, Markus  |d 1980-  |e VerfasserIn  |0 (DE-588)134044827  |0 (DE-627)692043934  |0 (DE-576)27468327X  |4 aut 
700 1 |a Beckmann, Matthias W.  |e VerfasserIn  |4 aut 
700 1 |a Hein, Alexander  |e VerfasserIn  |4 aut 
700 1 |a Belleville, Erik  |e VerfasserIn  |4 aut 
700 1 |a Uhrig, Sabrina  |e VerfasserIn  |4 aut 
700 1 |a Wimberger, Pauline  |e VerfasserIn  |4 aut 
700 1 |a Hielscher, Carsten  |e VerfasserIn  |4 aut 
700 1 |a Kurbacher, Christian M.  |e VerfasserIn  |4 aut 
700 1 |a Wuerstlein, Rachel  |e VerfasserIn  |4 aut 
700 1 |a Untch, Michael  |e VerfasserIn  |4 aut 
700 1 |8 2\p  |a Ţăran, Florin-Andrei  |d 1978-  |e VerfasserIn  |0 (DE-588)13392792X  |0 (DE-627)558737587  |0 (DE-576)278313485  |4 aut 
700 1 |a Enzinger, Hans-Martin  |e VerfasserIn  |4 aut 
700 1 |a Krabisch, Petra  |e VerfasserIn  |4 aut 
700 1 |a Welslau, Manfred  |e VerfasserIn  |4 aut 
700 1 |a Maasberg, Michael  |e VerfasserIn  |4 aut 
700 1 |a Hempel, Dirk  |e VerfasserIn  |4 aut 
700 1 |a Lux, Michael P.  |e VerfasserIn  |4 aut 
700 1 |a Michel, Laura L.  |e VerfasserIn  |4 aut 
700 1 |a Janni, Wolfgang  |e VerfasserIn  |4 aut 
700 1 |a Wallwiener, Diethelm  |e VerfasserIn  |4 aut 
700 1 |a Brucker, Sara Y.  |e VerfasserIn  |4 aut 
700 1 |8 3\p  |a Fehm, Tanja  |d 1971-  |e VerfasserIn  |0 (DE-588)120391759  |0 (DE-627)080645690  |0 (DE-576)292194064  |4 aut 
700 1 |8 4\p  |a Schneeweiss, Andreas  |d 1961-  |e VerfasserIn  |0 (DE-588)109972554  |0 (DE-627)632849630  |0 (DE-576)327251859  |4 aut 
773 0 8 |i Enthalten in  |t Geburtshilfe und Frauenheilkunde  |d Stuttgart : Thieme, 1980  |g 82(2022), 10, Seite 1055-1067  |h Online-Ressource  |w (DE-627)324451970  |w (DE-600)2026496-3  |w (DE-576)279447663  |x 1438-8804  |7 nnas  |a Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients data from the real-world registry PRAEGNANT = Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium : Real-World-Daten aus dem PRAEGNANT-Register 
773 1 8 |g volume:82  |g year:2022  |g number:10  |g pages:1055-1067  |g extent:13  |a Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients data from the real-world registry PRAEGNANT = Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium : Real-World-Daten aus dem PRAEGNANT-Register 
856 4 0 |u https://doi.org/10.1055/a-1880-0087  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://www.thieme-connect.de/DOI/DOI?10.1055/a-1880-0087  |x Verlag  |z lizenzpflichtig  |3 Volltext 
883 |8 1\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 2\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 3\p  |a cgwrk  |d 20250301  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
883 |8 4\p  |a cgwrk  |d 20241001  |q DE-101  |u https://d-nb.info/provenance/plan#cgwrk 
951 |a AR 
992 |a 20230209 
993 |a Article 
994 |a 2022 
998 |g 134044827  |a Wallwiener, Markus  |m 134044827:Wallwiener, Markus  |d 910000  |d 910400  |d 50000  |e 910000PW134044827  |e 910400PW134044827  |e 50000PW134044827  |k 0/910000/  |k 1/910000/910400/  |k 0/50000/  |p 11 
999 |a KXP-PPN1833842367  |e 4269553243 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"note":["Gesehen am 09.02.2023"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["authors: Tobias Engler, Peter A. Fasching, Diana Lüftner, Andreas D. Hartkopf, Volkmar Müller, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Markus Wallwiener, Matthias W. Beckmann, Alexander Hein, Erik Belleville, Sabrina Uhrig, Pauline Wimberger, Carsten Hielscher, Christian M. Kurbacher, Rachel Wuerstlein, Michael Untch, Florin-Andrei Taran, Hans-Martin Enzinger, Petra Krabisch, Manfred Welslau, Michael Maasberg, Dirk Hempel, Michael P. Lux, Laura L. Michel, Wolfgang Janni, Diethelm Wallwiener, Sara Y. Brucker, Tanja N. Fehm, Andreas Schneeweiss"]},"person":[{"role":"aut","family":"Englert","display":"Englert, Tobias","given":"Tobias"},{"display":"Fasching, Peter Andreas","given":"Peter Andreas","family":"Fasching","role":"aut"},{"display":"Lüftner, Diana","given":"Diana","role":"aut","family":"Lüftner"},{"role":"aut","family":"Hartkopf","display":"Hartkopf, Andreas D.","given":"Andreas D."},{"role":"aut","family":"Müller","given":"Volkmar","display":"Müller, Volkmar"},{"given":"Hans-Christian","display":"Kolberg, Hans-Christian","role":"aut","family":"Kolberg"},{"display":"Hadji, Peyman","given":"Peyman","family":"Hadji","role":"aut"},{"family":"Tesch","role":"aut","display":"Tesch, Hans","given":"Hans"},{"role":"aut","family":"Häberle","given":"Lothar","display":"Häberle, Lothar"},{"display":"Ettl, Johannes","given":"Johannes","family":"Ettl","role":"aut"},{"display":"Wallwiener, Markus","given":"Markus","role":"aut","family":"Wallwiener"},{"role":"aut","family":"Beckmann","display":"Beckmann, Matthias W.","given":"Matthias W."},{"role":"aut","family":"Hein","given":"Alexander","display":"Hein, Alexander"},{"display":"Belleville, Erik","given":"Erik","family":"Belleville","role":"aut"},{"family":"Uhrig","role":"aut","given":"Sabrina","display":"Uhrig, Sabrina"},{"given":"Pauline","display":"Wimberger, Pauline","role":"aut","family":"Wimberger"},{"given":"Carsten","display":"Hielscher, Carsten","family":"Hielscher","role":"aut"},{"family":"Kurbacher","role":"aut","display":"Kurbacher, Christian M.","given":"Christian M."},{"display":"Wuerstlein, Rachel","given":"Rachel","family":"Wuerstlein","role":"aut"},{"given":"Michael","display":"Untch, Michael","family":"Untch","role":"aut"},{"display":"Ţăran, Florin-Andrei","given":"Florin-Andrei","family":"Ţăran","role":"aut"},{"role":"aut","family":"Enzinger","given":"Hans-Martin","display":"Enzinger, Hans-Martin"},{"given":"Petra","display":"Krabisch, Petra","role":"aut","family":"Krabisch"},{"family":"Welslau","role":"aut","display":"Welslau, Manfred","given":"Manfred"},{"role":"aut","family":"Maasberg","given":"Michael","display":"Maasberg, Michael"},{"display":"Hempel, Dirk","given":"Dirk","role":"aut","family":"Hempel"},{"display":"Lux, Michael P.","given":"Michael P.","role":"aut","family":"Lux"},{"role":"aut","family":"Michel","display":"Michel, Laura L.","given":"Laura L."},{"family":"Janni","role":"aut","display":"Janni, Wolfgang","given":"Wolfgang"},{"display":"Wallwiener, Diethelm","given":"Diethelm","role":"aut","family":"Wallwiener"},{"family":"Brucker","role":"aut","display":"Brucker, Sara Y.","given":"Sara Y."},{"display":"Fehm, Tanja","given":"Tanja","role":"aut","family":"Fehm"},{"display":"Schneeweiss, Andreas","given":"Andreas","family":"Schneeweiss","role":"aut"}],"recId":"1833842367","title":[{"subtitle":"data from the real-world registry PRAEGNANT = Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium : Real-World-Daten aus dem PRAEGNANT-Register","title":"Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients","title_sort":"Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients"}],"id":{"doi":["10.1055/a-1880-0087"],"eki":["1833842367"]},"physDesc":[{"noteIll":"Diagramme","extent":"13 S."}],"titleTranslated":[{"translated":"Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium"}],"relHost":[{"titleAlt":[{"title":"GEBFRA"}],"disp":"Implementation of CDK4/6 inhibitors and its influence on the treatment landscape of advanced breast cancer patients data from the real-world registry PRAEGNANT = Einführung von CDK4/6-Hemmern und deren Auswirkung auf die Behandlungslandschaft bei Patientinnen mit Brustkrebs im fortgeschrittenen Stadium : Real-World-Daten aus dem PRAEGNANT-RegisterGeburtshilfe und Frauenheilkunde","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Erscheint monatlich","Gesehen am 08.11.2024"],"pubHistory":["Nachgewiesen 40.1980 -"],"language":["ger"],"part":{"text":"82(2022), 10, Seite 1055-1067","issue":"10","pages":"1055-1067","extent":"13","volume":"82","year":"2022"},"origin":[{"dateIssuedKey":"1980","publisherPlace":"Stuttgart ; New York, NY","publisher":"Thieme","dateIssuedDisp":"1980-"}],"title":[{"title_sort":"Geburtshilfe und Frauenheilkunde","title":"Geburtshilfe und Frauenheilkunde"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"doi":["10.1055/s-00000020"],"zdb":["2026496-3"],"issn":["1438-8804"],"eki":["324451970"]},"recId":"324451970"}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"2022-07-12"}]} 
SRT |a ENGLERTTOBIMPLEMENTA2022